BRIEF-Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses

Reuters03-11

March 11 (Reuters) - Atossa Therapeutics Inc ATOS.O:

ATOSSA THERAPEUTICS ANNOUNCES PLANS TO PURSUE METASTATIC BREAST CANCER INDICATION FOR $(Z)$-ENDOXIFEN AND CONTINUED ENGAGEMENT WITH FDA ON ADDITIONAL INDICATIONS

Source text: ID:nGNXc4yZR5

Further company coverage: ATOS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2518712740?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-11 22:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518712740","market":"nz","top_or_hot":-1,"title":"BRIEF-Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Atossa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> plans to develop durg to treat advanced breast cancer, talks with FDA on other uses</title></head><body><p><span>March 11 (Reuters)</span><span> - </span>Atossa Therapeutics Inc <span>ATOS.O</span>:</p><ul><li><p>ATOSSA THERAPEUTICS ANNOUNCES PLANS TO PURSUE METASTATIC BREAST CANCER INDICATION FOR <a href=\"https://laohu8.com/S/Z\">$(Z)$</a>-ENDOXIFEN AND CONTINUED ENGAGEMENT WITH FDA ON ADDITIONAL INDICATIONS</p></li></ul><p>Source text: <span>ID:nGNXc4yZR5</span></p><p>Further company coverage: <span>ATOS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-11 22:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Atossa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> plans to develop durg to treat advanced breast cancer, talks with FDA on other uses</title></head><body><p><span>March 11 (Reuters)</span><span> - </span>Atossa Therapeutics Inc <span>ATOS.O</span>:</p><ul><li><p>ATOSSA THERAPEUTICS ANNOUNCES PLANS TO PURSUE METASTATIC BREAST CANCER INDICATION FOR <a href=\"https://laohu8.com/S/Z\">$(Z)$</a>-ENDOXIFEN AND CONTINUED ENGAGEMENT WITH FDA ON ADDITIONAL INDICATIONS</p></li></ul><p>Source text: <span>ID:nGNXc4yZR5</span></p><p>Further company coverage: <span>ATOS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nFWN3PU0R9:1","article_id":"2518712740","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518712740","pubTimestamp":1741701897,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other usesMarch 11 (Reuters) - Atossa Therapeutics Inc ATOS.O:ATOSSA THERAPEUTICS ANNOUNCES PLANS TO ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ATOS":"Atossa Genetics Inc"},"translate_title":"简介-Atossa Therapeutics计划开发durg治疗晚期乳腺癌，并与FDA就其他用途进行谈判","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATOS":0.9},"content_text":"BRIEF-Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other usesMarch 11 (Reuters) - Atossa Therapeutics Inc ATOS.O:ATOSSA THERAPEUTICS ANNOUNCES PLANS TO PURSUE METASTATIC BREAST CANCER INDICATION FOR $(Z)$-ENDOXIFEN AND CONTINUED ENGAGEMENT WITH FDA ON ADDITIONAL INDICATIONSSource text: ID:nGNXc4yZR5Further company coverage: ATOS.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2518712740"}